{"id":102376,"date":"2026-03-27T10:52:39","date_gmt":"2026-03-27T08:52:39","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=102376"},"modified":"2026-03-27T10:51:52","modified_gmt":"2026-03-27T08:51:52","slug":"faconner-la-prochaine-evolution-de-limmuno-oncologie","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/","title":{"rendered":"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie"},"content":{"rendered":"\n<p><em>Mary Jane Hinrichs, Directrice mondiale du D\u00e9veloppement Pr\u00e9coce<\/em><\/p>\n\n\n\n<p><strong>Red\u00e9finir le prochain chapitre de l\u2019innovation en canc\u00e9rologie<\/strong><\/p>\n\n\n\n<p>En travaillant dans le d\u00e9veloppement pr\u00e9coce, j\u2019ai le privil\u00e8ge d\u2019assiter \u00e0 l\u2019\u00e9mergence de la prochaine g\u00e9n\u00e9ration de sciences du m\u00e9dicament se dessiner \u2013 et rares sont les domaines aussi captivants que l\u2019immuno\u2011oncologie (I\u2011O). Des premi\u00e8res donn\u00e9es en laboratoire aux avanc\u00e9es cliniques majeures, il apparait clairement que nous entrons dans une nouvelle \u00e8re, avec le potentiel de r\u00e9sultats v\u00e9ritablement transformateurs pour les patients.<\/p>\n\n\n\n<p>Ces progr\u00e8s t\u00e9moignent d\u2019un niveau de sophistication croissant \u2013 non seulement dans notre compr\u00e9hension du syst\u00e8me immunitaire et de son interaction avec le cancer, mais aussi dans la mani\u00e8re dont nous r\u00e9pondons aux d\u00e9fis concrets auxquels sont confront\u00e9s les professionnels de sant\u00e9, les patients et leurs familles. Malgr\u00e9 des avanc\u00e9es majeures en I\u2011O, les r\u00e9ponses des patients demeurent variables et les toxicit\u00e9s li\u00e9es au syst\u00e8me immunitaire fr\u00e9quentes, soulignant la n\u00e9cessit\u00e9 d\u2019approches plus fines et plus cibl\u00e9es.<sup>1<\/sup><\/p>\n\n\n\n<p><strong>De \u00ab<\/strong><strong>desserrer<\/strong><strong> les freins<\/strong><strong>\u202f<\/strong><strong>\u00bb<\/strong><strong> aux approches cibl<\/strong><strong>\u00e9<\/strong><strong>es<\/strong><\/p>\n\n\n\n<p>Les immunoth\u00e9rapies de premi\u00e8re g\u00e9n\u00e9ration ont d\u00e9montr\u00e9 que desserrer les freins des cellules immunitaires pouvait induire des r\u00e9ponses significatives, mais elles ont \u00e9galement r\u00e9v\u00e9l\u00e9 les limites d\u2019une activation immunitaire trop large. Ces enseignements fa\u00e7onnent aujourd\u2019hui les approches de nouvelle g\u00e9n\u00e9ration, qui mobilisent le syst\u00e8me immunitaire avec davantage de pr\u00e9cision\u202f: en ciblant des voies sp\u00e9cifiques et des types cellulaires pour une r\u00e9ponse immunitaire plus coordonn\u00e9e et adapt\u00e9e.<sup>2<\/sup><\/p>\n\n\n\n<p>En synchronisant les premi\u00e8re lignes de d\u00e9fenses rapides de du syst\u00e8me immunitaire avec sa r\u00e9ponse tardive plus cibl\u00e9e, ces th\u00e9rapies \u00e9mergentes pourraient offrir une activit\u00e9 anticanc\u00e9reuse plus profonde tout en garantissant une ma\u00eetrise de la tol\u00e9rance.<sup>2,3<\/sup><\/p>\n\n\n\n<p>C\u2019est cette promesse qui guide notre travail chez Ipsen. Fond\u00e9s sur la pr\u00e9cision, la s\u00e9lectivit\u00e9 et une compr\u00e9hension approfondie de la biologie du cancer, nous progressons un portefeuille croissant de programmes en immuno\u2011oncologie, couvrant les tumeurs solides et les cancers du sang, avec des activateurs de cellules T, des engageurs de cellules T ainsi que des anticorps\u2011conjugu\u00e9s&nbsp; cibl\u00e9s. Je suis particuli\u00e8rement inspir\u00e9 par le potentiel des approches d\u2019I\u2011O nouvelle g\u00e9n\u00e9ration \u00e0offrir des traitements mieux tol\u00e9r\u00e9s aux patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb, un domaine o\u00f9 les besoins m\u00e9dicaux non satisfaits restent extr\u00eamement \u00e9lev\u00e9s.<\/p>\n\n\n\n<p><strong>Regard vers l\u2019avenir<\/strong><\/p>\n\n\n\n<p>Le rythme des avanc\u00e9es en I\u2011O est remarquable, mais la v\u00e9ritable mesure du succ\u00e8s ne r\u00e9side pas dans la sophistication scientifique. Elle tient dans la capacit\u00e9 de mettre cette pr\u00e9cision au service des patients vivant avec des cancers comme la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb, o\u00f9 les options th\u00e9rapeutiques actuelles demeurent insuffisantes. Les outils deviennent plus performants. La question est d\u00e9sormais de savoir \u00e0 quelle vitesse nous pourrons combler cet \u00e9cart.<ins><\/ins><\/p>\n\n\n\n    <!--Accordion Cards Start Here-->\n    <section class=\"accordion bg-color-disabled\"  data-according-id=\"1366443597\">\n        <div class=\"container\">\n            <div class=\"row\">\n                <!--Accordion info section-->\n                <div class=\"column-1 col-xl-12 col-md-12 col-sm-12\">\n                    <div class=\"accordian-info\">\n                        <h3 class=\"accordian-heading hidden heading-three\" role=\"heading\" aria-level=\"2\">\n                                                    <\/h3>\n                        <p class=\"accordian-summary hidden\"><\/p>\n                    <\/div>\n                <\/div><!--Accordion info section over here -->\n\n                <div class=\"col-xl-12 col-lg-12 col-md-12 col-sm-12\">\n                    <div class=\"accordion accor-group\" id=\"accordionExample1366443597\">\n                         \n                                    <!-- Accordion with Expandable panel & FAQs -->\n                                    <div class=\"accordion-item accor-item\">\n                                        <p  role=\"heading\" aria-level=\"3\" class=\"accordion-header accor-head-para\" id=\"expHeading0\">\n                                            <button class=\"accordion-button accor-btn collapsed\" type=\"button\" data-bs-toggle=\"collapse\" data-bs-target=\"#expHeading13664435970\" aria-expanded=\"false\" aria-controls=\"expHeading13664435970\">\n                                                R\u00e9f\u00e9rences                                            <\/button>\n                                        <\/p>\n                                        <div id=\"expHeading13664435970\" class=\"accordion-collapse collapse \" aria-labelledby=\"expHeading0\" data-bs-parent=\"#accordionExample1366443597\">\n                                            <div class=\"accordion-body\">\n                                                <div class=\"accordion-data\">\n                                                    <p><ol>\n<li>Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review.\u00a0<em>Front Immunol<\/em>. 2023;14:1167975. Published 2023 May 25. doi:10.3389\/fimmu.2023.1167975<\/li>\n<li>Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.\u00a0<em>Journal of Clinical Medicine<\/em>. 2024; 13(21):6537. <a href=\"https:\/\/doi.org\/10.3390\/jcm13216537\">https:\/\/doi.org\/10.3390\/jcm13216537<\/a><\/li>\n<li>Li C, Yu X, Han X, et al. Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy.\u00a0<em>iScience<\/em>. 2024;27(9):110750. Published 2024 Aug 17. doi:10.1016\/j.isci.2024.110750<\/li>\n<\/ol>\n<\/p>\n                                                    <div class=\"cta-block hidden\" >\n                                                                                                            <\/div>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                    <\/div>\n                                                <\/div>\n                <\/div> \n            <\/div>\n        <\/div>\n    <\/section>\n    <!--Accordion Cards End Here-->\n","protected":false},"excerpt":{"rendered":"<p>Mary Jane Hinrichs, Directrice mondiale du D\u00e9veloppement Pr\u00e9coce Red\u00e9finir le prochain chapitre de l\u2019innovation en canc\u00e9rologie En travaillant dans le<\/p>\n","protected":false},"author":97,"featured_media":102381,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[6024],"tags":[],"class_list":["post-102376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oncology-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie - Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie - Global\" \/>\n<meta property=\"og:description\" content=\"Mary Jane Hinrichs, Directrice mondiale du D\u00e9veloppement Pr\u00e9coce Red\u00e9finir le prochain chapitre de l\u2019innovation en canc\u00e9rologie En travaillant dans le\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-27T08:52:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"emie\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"emie\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/\"},\"author\":{\"name\":\"emie\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4\"},\"headline\":\"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie\",\"datePublished\":\"2026-03-27T08:52:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/\"},\"wordCount\":538,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png\",\"articleSection\":[\"Oncologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/\",\"name\":\"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie - Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png\",\"datePublished\":\"2026-03-27T08:52:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4\",\"name\":\"emie\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g\",\"caption\":\"emie\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie - Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/","og_locale":"fr_FR","og_type":"article","og_title":"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie - Global","og_description":"Mary Jane Hinrichs, Directrice mondiale du D\u00e9veloppement Pr\u00e9coce Red\u00e9finir le prochain chapitre de l\u2019innovation en canc\u00e9rologie En travaillant dans le","og_url":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/","og_site_name":"Global","article_published_time":"2026-03-27T08:52:39+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png","type":"image\/png"}],"author":"emie","twitter_card":"summary_large_image","twitter_creator":"@ipsengroup","twitter_site":"@ipsengroup","twitter_misc":{"Written by":"emie","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/"},"author":{"name":"emie","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4"},"headline":"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie","datePublished":"2026-03-27T08:52:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/"},"wordCount":538,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png","articleSection":["Oncologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/","url":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/","name":"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie - Global","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png","datePublished":"2026-03-27T08:52:39+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/oncology-fr\/faconner-la-prochaine-evolution-de-limmuno-oncologie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Fa\u00e7onner la prochaine \u00e9volution de l\u2019immuno\u2011oncologie"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/a0f231a95044132e1295dd6b00f339b4","name":"emie","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e3bc24640199849cf7c9cfaa79cb49dc93e3d4e03a9e50a0dc791bd1a408a70f?s=96&d=mm&r=g","caption":"emie"}}]}},"jetpack_featured_media_url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2026\/03\/Tovo-CHMP_Internal-FR-2.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/102376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/97"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/comments?post=102376"}],"version-history":[{"count":3,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/102376\/revisions"}],"predecessor-version":[{"id":102384,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/102376\/revisions\/102384"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/102381"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=102376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=102376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=102376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}